BDH1: A Potential Drug Target and Biomarker for Short Chain Dehydrogenase/Reductase Family 9C

Target Name: BDH1

NCBI ID: G622

BDH1: A Potential Drug Target and Biomarker for Short Chain Dehydrogenase/Reductase Family 9C

Short chain dehydrogenase/reductase family 9C (BDH1) is a gene that encodes a protein involved in the detoxification of small molecules, particularly those that are toxic or harmful. This gene is a promising candidate for drug targeting due to its involvement in various cellular processes that are crucial for human health. In this article, we will explore the biology and potential drug targets of BDH1.

BDH1 Expression and Functions

BDH1 is a 17 kDa protein that is expressed in various tissues, including brain, heart, liver, and muscle. It is primarily localized to the endoplasmic reticulum (ER) and is considered as a peripheral protein. The protein is involved in the detoxification of small molecules, including xenobiotics, such as drugs, toxins, and environmental pollutants.

BDH1 functions as a critical enzyme in the detoxification pathway. It catalyzes the conversion of 2-hydroxy-boxy-acetone (2-HBA) to 2-hydroxy-butyrate (2-HBr) using NAD+ as a cofactor. This reaction is critical for the detoxification of many xenobiotics, including drugs and environmental toxins.

BDH1's Role in Toxin Detoxification

BDH1 is highly expressed in the liver and other organs, which makes it an attractive target for drug detoxification. Many drugs, including toxins and environmental pollutants, are detoxified by the liver before they reach the rest of the body. The detoxification process involves the metabolism of these drugs by enzymes such as BDH1.

The use of drugs that are toxic to human health is a major public health concern. The detoxification process of these drugs can be enhanced by the expression of BDH1, which can help to reduce the amount of drug that is absorbed into the body.

BDH1 as a Biomarker

BDH1 has also been used as a biomarker for various diseases, including cancer, neurodegenerative diseases, and neuropsychiatric disorders.

In neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, the levels of BDH1 have been found to be decreased in the brain. This suggests that these diseases may be characterized by decreased BDH1 function, which could potentially be a therapeutic target.

In cancer, BDH1 has been found to be involved in the detoxification of chemotherapy drugs. This suggests that BDH1 may be a useful biomarker for the assessment of the effectiveness of cancer treatments.

BDH1 also has been found to be involved in the detoxification of environmental toxins, such as polychlorinated biphenyls (PCBs) and polycyclic aromatic hydrocarbons (PAHs). These toxins are commonly found in various environmental media and have been linked to various health problems, including reproductive and nervous system disorders.

BDH1's Potential as a Drug Target

The potential drug targets of BDH1 are numerous and varied.

One potential drug target is the inhibition of BDH1 activity, which could help to reduce the detoxification of drugs and other harmful substances. This could be achieved by inhibiting the activity of BDH1's catalytic active site, which is responsible for the conversion of 2-hydroxy-boxy-acetone to 2-hydroxy-butyrate.

Another potential drug target of BDH1 is the inhibition of its synthesis, which could help to reduce the levels of BDH1 in various tissues. This could be achieved by inhibiting the activity of enzymes involved in BDH1 synthesis, such as DNA polymerase I and topoisomerase I.

In addition to these drug

Protein Name: 3-hydroxybutyrate Dehydrogenase 1

More Common Targets